




Healthcare Industry News: Mentor Corp
News Release - January 23, 2009
Johnson & Johnson Completes Acquisition of Mentor Corporation
NEW BRUNSWICK, N.J., Jan. 23 (Healthcare Sales & Marketing Network) -- Johnson & Johnson (NYSE: JNJ ) today announced the completion of its previously announced acquisition of Mentor Corporation (NYSE: MNT ), a leading supplier of medical products for the global aesthetic market. Mentor is expected to operate as a stand-alone business unit reporting through ETHICON, Inc., a Johnson & Johnson company and a leading provider of suture, mesh and other products for a wide range of surgical procedures.According to Gary Pruden, Company Group Chairman, Johnson & Johnson, with responsibility for the ETHICON Franchise, "Mentor will become the cornerstone of a broader Johnson & Johnson strategy for aesthetic medicine -- serving both consumers and medical professionals. We will use our combined strengths and experience to build a market-leading aesthetic business that capitalizes on Johnson & Johnson's broad-based commercial capabilities, worldwide surgical care footprint, and clinical scientific capabilities."
About Johnson & Johnson
Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Source: Johnson & Johnson
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
New Drug Application Initiated with U.S. FDA for TAR-200, the First and Only Intravesical Drug Releasing System for Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder CancerJohnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients